A Clinical Analysis of Brain Metastasis in Gynecologic Cancer: a Retrospective Multi-institute Analysis

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2015 Jan 2

PMID 25552885

Citations 18

Authors

Young Zoon Kim

Jae Hyun Kwon

Soyi Lim

Affiliations

Soon will be listed here.

Abstract

This study analyzes the clinical characteristics of the brain metastasis (BM) of gynecologic cancer based on the type of cancer. In addition, the study examines the factors influencing the survival. Total 61 BM patients of gynecologic cancer were analyzed retrospectively from January 2000 to December 2012 in terms of clinical and radiological characteristics by using medical and radiological records from three university hospitals. There were 19 (31.1%) uterine cancers, 32 (52.5%) ovarian cancers, and 10 (16.4%) cervical cancers. The mean interval to BM was 25.4 months (21.6 months in ovarian cancer, 27.8 months in uterine cancer, and 33.1 months in cervical cancer). The mean survival from BM was 16.7 months (14.1 months in ovarian cancer, 23.3 months in uterine cancer, and 8.8 months in cervical cancer). According to a multivariate analysis of factors influencing survival, type of primary cancer, Karnofsky performance score, status of primary cancer, recursive partitioning analysis class, and treatment modality, particularly combined therapies, were significantly related to the overall survival. These results suggest that, in addition to traditional prognostic factors in BM, multiple treatment methods such as neurosurgery and combined chemoradiotherapy may play an important role in prolonging the survival for BM patients of gynecologic cancer.

Citing Articles

Brain Metastasis in Endometrial Cancer: A Systematic Review.

Sambataro D, Gebbia V, Bonasera A, Quattrocchi A, Caputo G, Vinci E Cancers (Basel). 2025; 17(3).

PMID: 39941769 PMC: 11816136. DOI: 10.3390/cancers17030402.

Prognostic features of endometrial cancer metastasis to the central nervous system.

Kuznicki M, Mallen A, Ha K, McClung E, Castaneda A, Cao B PLoS One. 2022; 17(8):e0268794.

PMID: 36018828 PMC: 9417007. DOI: 10.1371/journal.pone.0268794.

Incidence and risk factors for the development of cerebral metastasis in cervical cancer patients.

de Brito Rangel J, Giglio A, Cardozo C, Bergmann A, Thuler L J Gynecol Oncol. 2022; 33(5):e58.

PMID: 35712971 PMC: 9428298. DOI: 10.3802/jgo.2022.33.e58.

Brain Metastases from Gynecologic Malignancies.

Karpathiou G, Camy F, Chauleur C, Dridi M, Dal Col P, Peoch M Medicina (Kaunas). 2022; 58(4).

PMID: 35454386 PMC: 9028561. DOI: 10.3390/medicina58040548.

Brain metastases: the role of clinical imaging.

Derks S, van der Veldt A, Smits M Br J Radiol. 2021; 95(1130):20210944.

PMID: 34808072 PMC: 8822566. DOI: 10.1259/bjr.20210944.

References

Kolomainen D, Larkin J, Badran M, AHern R, King D, Fisher C . Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol. 2002; 20(4):982-6. DOI: 10.1200/JCO.2002.20.4.982. View

Mayer R, Berkowitz R, GRIFFITHS C . Central nervous system involvement by ovarian carcinoma: a complication of prolonged survivial with metastatic disease. Cancer. 1978; 41(2):776-83. DOI: 10.1002/1097-0142(197802)41:2<776::aid-cncr2820410253>3.0.co;2-e. View

Tangjitgamol S, Levenback C, Beller U, Kavanagh J . Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer. 2004; 14(3):399-422. DOI: 10.1111/j.1048-891x.2004.14326.x. View

Anupol N, Ghamande S, Odunsi K, Driscoll D, Lele S . Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. Gynecol Oncol. 2002; 85(3):487-92. DOI: 10.1006/gyno.2002.6653. View

Salvati M, Cervoni L . Solitary cerebral metastasis from ovarian carcinoma: report of 4 cases. J Neurooncol. 1994; 19(1):75-7. DOI: 10.1007/BF01051051. View

Weber B, Conroy T, Spaeth D . Brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001; 10(5):366-371. DOI: 10.1046/j.1525-1438.2000.010005366.x. View

Wronski M, De Palma P, Arbit E . Leiomyosarcoma of the uterus metastatic to brain: a case report and a review of the literature. Gynecol Oncol. 1994; 54(2):237-41. DOI: 10.1006/gyno.1994.1201. View

Muggia F, Blessing J, Sorosky J, Reid G . Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002; 20(9):2360-4. DOI: 10.1200/JCO.2002.08.171. View

Jemal A, Thomas A, Murray T, Thun M . Cancer statistics, 2002. CA Cancer J Clin. 2002; 52(1):23-47. DOI: 10.3322/canjclin.52.1.23. View

10.

Gadducci A, Tana R, Teti G, Fanucchi A, Pasqualetti F, Cionini L . Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature. Anticancer Res. 2008; 27(6C):4403-9. View

11.

Kim T, Song S, Kim C, Kim W, Choi C, Lee J . Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer. 2007; 17(6):1252-7. DOI: 10.1111/j.1525-1438.2007.00941.x. View

12.

Lee Y, Park N, Kim J, Song Y, Kang S, Lee H . Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer. Gynecol Oncol. 2008; 108(3):505-9. DOI: 10.1016/j.ygyno.2007.11.027. View

13.

Cormio G, Maneo A, Parma G, Pittelli M, Miceli M, Bonazzi C . Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review. Ann Oncol. 1995; 6(6):571-4. DOI: 10.1093/oxfordjournals.annonc.a059246. View

14.

McMeekin D, Kamelle S, Vasilev S, Tillmanns T, Gould N, Scribner D . Ovarian cancer metastatic to the brain: what is the optimal management?. J Surg Oncol. 2001; 78(3):194-200; discussion 200-1. DOI: 10.1002/jso.1149. View

15.

Monaco 3rd E, Kondziolka D, Mongia S, Niranjan A, Flickinger J, Lunsford L . Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery. Cancer. 2008; 113(9):2610-4. DOI: 10.1002/cncr.23868. View

16.

Richards G, Khuntia D, Mehta M . Therapeutic management of metastatic brain tumors. Crit Rev Oncol Hematol. 2006; 61(1):70-8. DOI: 10.1016/j.critrevonc.2006.06.012. View

17.

Hardy J, Harvey V . Cerebral metastases in patients with ovarian cancer treated with chemotherapy. Gynecol Oncol. 1989; 33(3):296-300. DOI: 10.1016/0090-8258(89)90515-5. View

18.

Cormio G, Loizzi V, Falagario M, Lissoni A, Resta L, Selvaggi L . Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994. Int J Gynaecol Obstet. 2011; 114(2):133-6. DOI: 10.1016/j.ijgo.2011.02.014. View

19.

Geisler J, Geisler H . Brain metastases in epithelial ovarian carcinoma. Gynecol Oncol. 1995; 57(2):246-9. DOI: 10.1006/gyno.1995.1134. View

20.

Benedet J, Bender H, Jones 3rd H, Ngan H, Pecorelli S . FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000; 70(2):209-62. View